Genmab A/S

Common Name
Genmab
Country
Denmark
Sector
Healthcare
Industry
Biotechnology
Employees
2,639
Ticker
GMAB
Exchange
NASDAQ COPENHAGEN A/S
Description
Genmab A/S is an international biotechnology company focused on the research, development, and commercialization of innovative antibody-based therapies. Its primary mission is to transform the treatme...

Genmab's Financial Statements Preview

Below are the financial statements of Genmab, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in billions of DKK
2024
2023
2022
Revenue
21.53a
16.47a
14.51a
Cost of product sales
-0.99a
-0.23a
0a
Research and development expenses
-9.75a
-7.63a
-5.56a
Selling, general and administrative expenses
-3.79a
-3.3a
-2.68a
Acquisition and integration related charges
-0.3a
0a
0a
Total costs and operating expenses
-14.82a
-11.15a
-8.24a
Operating profit
6.7a
5.32a
6.27a
Financial income
4.44a
1.94a
3.19a
Financial expenses
-1.98a
-1.62a
-2.51a
Net profit before tax
9.16a
5.64a
6.95a
Corporate tax
-1.32a
-1.29a
-1.49a
Net profit
7.84a
4.35a
5.45a
Download Data

Verified Sources Behind Genmab’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Genmab’s data sources below and access millions more through our Disclosure Search.

a. Genmab's Annual Report 2024
a. Genmab's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?